What is the most important complication to monitor for in a patient started on Farxiga (dapagliflozin), an SGLT2 inhibitor, given its mechanism of action?

Greatest Concern with Farxiga (Dapagliflozin) and SGLT2 Inhibitors

The greatest concern for complications with Farxiga and other SGLT2 inhibitors is euglycemic diabetic ketoacidosis (DKA), a potentially life-threatening condition that can occur even with normal or only modestly elevated blood glucose levels (<250 mg/dL).

Understanding the Critical Risk: Euglycemic Ketoacidosis

While SGLT2 inhibitors like Farxiga have multiple mechanism-related complications, euglycemic DKA stands out as the most dangerous because:

• It can be fatal and is easily missed due to unexpectedly normal glucose levels 1, 2
• The FDA specifically warns that ketoacidosis events have been reported as fatal in patients with type 2 diabetes using SGLT2 inhibitors 2
• Patients may present with blood glucose <14 mmol/L (<250 mg/dL), making diagnosis challenging 3
• The incidence is approximately 0.1%, but the consequences are severe 3, 4

High-Risk Patients Requiring Extra Vigilance

Patients requiring insulin are at particular risk for euglycemic DKA 1. Additional risk factors include:

• Insulin deficiency or missed insulin doses 4, 2
• Acute illness, surgery, trauma, or prolonged fasting 4
• Very low-carbohydrate or ketogenic diets (SGLT2i eliminate 60-100g glucose/day) 4
• Alcohol abuse 4
• Volume depletion 4, 2
• History of pancreatitis or pancreatic surgery 2

Critical Warning Signs to Monitor

Educate patients to immediately discontinue Farxiga and seek emergency care if they develop 3, 2:

• Shortness of breath
• Nausea and vomiting
• Abdominal pain
• Confusion or lethargy
• Anorexia and excessive thirst
• Generalized malaise

Check ketones (blood or urine) regardless of blood glucose level if these symptoms occur 1, 2.

Essential Management Strategies

To mitigate ketoacidosis risk 1:

• Maintain at least low-dose insulin in insulin-requiring patients 1
• Pause SGLT2 inhibitors during acute illness or stressors ("sick day management") 3, 5
• Consider ketone monitoring in high-risk patients 1
• Educate all patients on signs/symptoms and when to stop the medication 2

Other Important Mechanism-Related Complications

Volume Depletion and Hypotension

SGLT2 inhibitors cause osmotic diuresis, leading to 4, 2:

• Symptomatic hypotension, syncope, and dehydration
• Systolic BP reduction of 4-6 mmHg, diastolic 1-2 mmHg 4
• Higher risk in patients with eGFR <60 mL/min/1.73 m², elderly patients, or those on loop diuretics 2
• Assess volume status before initiating and monitor for signs of hypotension 2
• Careful attention needed when combining with ARNIs and loop diuretics 3, 5

Genitourinary Infections

Genital mycotic infections are the most common adverse effect 3, 5:

• Occur in 6-10% of patients (vs. 1% with placebo) 1
• Women have 10-15% risk; uncircumcised men and those with prior infections are at highest risk 3, 5
• Most infections are easily treated with antifungals and don't require drug discontinuation 3, 5
• Rare but serious: Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported 1, 2

Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have occurred 4, 2.

Acute Kidney Injury Risk

Despite long-term renal protection, short-term concerns include 4:

• Initial eGFR decline of 15-25% (usually reversible within 1-3 months) 3, 5
• AKI risk from osmotic diuresis and volume contraction 4
• This initial decline is expected and hemodynamically mediated—similar to ACE inhibitors—and should not prompt discontinuation 5
• Higher risk with pre-existing hypovolemia, severe CKD, heart failure, or concurrent nephrotoxic medications 4

Hypoglycemia (Context-Dependent)

SGLT2 inhibitors have low intrinsic hypoglycemia risk but increase risk when combined with 1, 3, 2:

• Insulin secretagogues (sulfonylureas, meglitinides)
• Insulin therapy
• Consider reducing doses of these agents when initiating Farxiga 2

Common Pitfall to Avoid

Do not discontinue SGLT2 inhibitors prematurely due to initial eGFR decline. This hemodynamic effect is expected, protective long-term, and generally resolves within 1-3 months 3, 5. The drug can be continued even if eGFR falls below initiation thresholds unless the patient is not tolerating treatment or dialysis is initiated 1.

Contraindications and Special Populations

• Contraindicated in type 1 diabetes due to markedly increased ketoacidosis risk 3, 2
• Not recommended for new initiation with eGFR <25 mL/min/1.73 m² for dapagliflozin, though may continue if already established 1
• Use caution in patients on ketogenic diets given the 60-100g/day glucose elimination 4